{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:33:45Z","timestamp":1778790825615,"version":"3.51.4"},"reference-count":105,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n<jats:title> Background:<\/jats:title>\n<jats:p>Primary and metastatic bone tumor incidence has increased in the previous\nyears. Pain is a common symptom and is one of the most important related factors to the decrease of\nquality of life in patients with bone tumor. Different pain management strategies are not completely\neffective and many patients afflicted by cancer pain cannot be controlled properly. In this sense, we\nneed to elucidate the neurophysiology of cancer-induced pain, contemplating other components\nsuch as inflammation, neuropathies and cognitive components regarding bone tumors, and thus\npave the way for novel therapeutic approaches in this field.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>This study aims to identify the neurophysiology of the mechanisms related to pain management\nin bone tumors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Advanced searches were performed in scientific databases: PubMed, ProQuest, EBSCO,\nand the Science Citation index to get information about the neurophysiology mechanisms related to\npain management in bone tumors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The central and peripheral mechanisms that promote bone cancer pain are poorly understood.\nStudies have shown that bone cancer could be related to neurochemicals produced by tumor\nand inflammatory cells, coupled with peripheral sensitization due to nerve compression and injury\ncaused by tumor growth. The activity of mesolimbic dopaminergic neurons, substance P, cysteine\/\nglutamate antiporter, and other neurochemical dynamics brings us putative strategies to suggest\nbetter and efficient treatments against pain in cancer patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Cancer-induced bone pain could include neuropathic and inflammatory pain, but with\ndifferent modifications to the periphery tissue, nerves and neurochemical changes in different neurological\nlevels. In this sense, we explore opportunity areas in pharmacological and nonpharmacological\npain management, according to pain-involved mechanisms in this study.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x18666201111112748","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T05:18:46Z","timestamp":1605158326000},"page":"308-319","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neurophysiological Mechanisms Related to Pain Management in Bone Tumors"],"prefix":"10.2174","volume":"19","author":[{"given":"Pablo","family":"Romero-Morelos","sequence":"first","affiliation":[{"name":"Universidad Estatal del Valle de Ecatepec, Estado de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Ruvalcaba-Paredes","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Rehabilitacion, \u201cLuis Guillermo Ibarra, Ibarra\u201d, SSA, Ciudad de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Garciadiego-C\u00e1zares","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Rehabilitacion, \u201cLuis Guillermo Ibarra, Ibarra\u201d, SSA, Ciudad de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"P\u00e9rez-Santos","sequence":"additional","affiliation":[{"name":"Direccion De Innovacion Y Transferencia De Conocimiento, Benemerita Universidad Autonoma De Puebla, Puebla,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Reyes-Long","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Rehabilitacion, \u201cLuis Guillermo Ibarra, Ibarra\u201d, SSA, Ciudad de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Alfaro-Rodriguez","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Rehabilitacion, \u201cLuis Guillermo Ibarra, Ibarra\u201d, SSA, Ciudad de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Salcedo","sequence":"additional","affiliation":[{"name":"Laboratorio de Oncologia Genomica, Centro Medico Nacional Siglo XXI, IMSS, Ciudad de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Mancilla-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Escuela Superior de Medicina, Instituto Politecnico Nacional, Ciudad de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Bandala","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Rehabilitacion, \u201cLuis Guillermo Ibarra, Ibarra\u201d, SSA, Ciudad de Mexico,Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0304-3959(79)90175-1","volume":"6","author":"Merskey H.","year":"1979","unstructured":"Merskey H.; Albe Fessard D.; Bonica J.J.; Carmon A.; Dubner R.; Kerr F.W.L.; Lindblom U.; Mumford J.M.; Nathan P.W.; Noordenbos W.; Pagni C.A.; Renaer M.J.; Sternbach R.A.; Sunderland S.; Recommended by the IASP Subcommittee on Taxonomy. Pain terms: a list with definitions and notes on usage. Pain 1979,6(3),249-252","journal-title":"Pain"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4321\/S0212-71992007001100010","volume":"24","author":"Khosravi S.P.","year":"2007","unstructured":"Khosravi S.P.; del Castillo R.A.; P\u00e9rez M.G.; Manejo del dolor oncol\u00f3gico. An Med Interna (Madrid) 2007,24,554-557","journal-title":"An Med Interna (Madrid)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1097\/j.pain.0000000000000613","volume":"157","author":"Williams A.C.","year":"2016","unstructured":"Williams A.C.; Craig K.D.; Updating the definition of pain. Pain 2016,157(11),2420-2423","journal-title":"Pain"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000813","volume":"5","author":"Bernstein L.R.","year":"2020","unstructured":"Bernstein L.R.; A pragmatic, general definition of pain. Pain Rep 2020,5(2)","journal-title":"Pain Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s11914-018-0493-1","volume":"16","author":"Havelin J.","year":"2018","unstructured":"Havelin J.; King T.; Mechanisms underlying bone and joint pain. Curr Osteoporos Rep 2018,16(6),763-771","journal-title":"Curr Osteoporos Rep"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.annonc.2020.01.001","volume":"31","author":"Solans M.","year":"2020","unstructured":"Solans M.; Chan D.S.M.; Mitrou P.; Norat T.; Romaguera D.; A systematic review and meta-analysis of the 2007 WCRF\/AICR score in relation to cancer-related health outcomes. Ann Oncol 2020,31(3),352-368","journal-title":"Ann Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40138-018-0170-9","volume":"6","author":"Money S.","year":"2018","unstructured":"Money S.; Garber B.; Management of cancer pain. Curr Emerg Hosp Med Rep 2018,6,141-146","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nrn1914","volume":"7","author":"Mantyh P.W.","year":"2006","unstructured":"Mantyh P.W.; Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006,7(10),797-809","journal-title":"Nat Rev Neurosci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11916-017-0613-0","volume":"21","author":"Candido K.D.","year":"2017","unstructured":"Candido K.D.; Kusper T.M.; Knezevic N.N.; New Cancer Pain Treatment Options. Curr Pain Headache Rep 2017,21(2),12","journal-title":"Curr Pain Headache Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"6451","DOI":"10.7314\/APJCP.2015.16.15.6451","volume":"16","author":"DelaGarza-Montano P.","year":"2015","unstructured":"DelaGarza-Montano P.; Estrada-Villase\u00f1or E.; Dominguez R.R.; Martinez-Lopez V.; Avila-Luna A.; Alfaro-Rodriguez A.; Garciadiego-Cazares D.; Carlos A.; Hernandez-Perez A.D.; Bandala C.; Epidemiological Aspects of osteosarcoma, giant cell tumor and chondrosarcoma musculoskeletal tumors--experience of the National Rehabilitation Institute, Mexico City. Asian Pac J Cancer Prev 2015,16(15),6451-6455","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/pbc.25963","volume":"63","author":"Marko T.A.","year":"2016","unstructured":"Marko T.A.; Diessner B.J.; Spector L.G.; Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison. Pediatr Blood Cancer 2016,63(6),1006-1011","journal-title":"Pediatr Blood Cancer"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s11914-018-0489-x","volume":"16","author":"Yoneda T.","year":"2018","unstructured":"Yoneda T.; Hiasa M.; Okui T.; Crosstalk between sensory nerves and cancer in bone. Curr Osteoporos Rep 2018,16(6),648-656","journal-title":"Curr Osteoporos Rep"},{"key":"ref=13","year":"2007","unstructured":"WHO Normative Guidelines on Pain Management2007 http:\/\/www.who.int\/medicines\/areas\/quality_safety\/delphi_study_pain_guidelines.pdf"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cnc.2017.08.002","volume":"29","author":"Orr P.M.","year":"2017","unstructured":"Orr P.M.; Shank B.C.; Black A.C.; The role of pain classification systems in pain management. Crit Care Nurs Clin North Am 2017,29(4),407-418","journal-title":"Crit Care Nurs Clin North Am"},{"key":"ref=15","year":"2007","unstructured":"European Commission Health in the European Union: Special EUROBAROMETER2007 http:\/\/ec.europa.eu\/health\/ph_publication\/eb_health_en.pdf"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/S0140-6736(99)01306-9","volume":"353","author":"Cervero F.","year":"1999","unstructured":"Cervero F.; Laird J.M.A.; Visceral pain. Lancet 1999,353(9170),2145-2148","journal-title":"Lancet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neurol.2018.09.016","volume":"175","author":"Bouhassira D.","year":"2019","unstructured":"Bouhassira D.; Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris) 2019,175(1-2),16-25","journal-title":"Rev Neurol (Paris)"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(99)03313-9","volume":"353","author":"Carr D.B.","year":"1999","unstructured":"Carr D.B.; Goudas L.C.; Acute pain. Lancet 1999,353(9169),2051-2058","journal-title":"Lancet"},{"key":"ref=19","author":"Wurhman E.","year":"2011","unstructured":"Wurhman E.; Cooney M.F.;  Acute pain: assessment and treatment Medscape 2011 https:\/\/www.medscape.com\/viewarticle\/735034_print","journal-title":"Acute pain: assessment and treatment Medscape"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00296-016-3481-8","volume":"37","author":"Hylands-White N.","year":"2017","unstructured":"Hylands-White N.; Duarte R.V.; Raphael J.H.; An overview of treatment approaches for chronic pain management. Rheumatol Int 2017,37(1),29-42","journal-title":"Rheumatol Int"},{"key":"ref=21","first-page":"209","year":"1994","unstructured":"Part III: Pain Terms, A Current List with Definitions and Notes on Usage Classification of Chronic Pain, Second Edition, IASP Task Force on Taxonomy, edited by H Merskey and N Bogduk, ISAP Press, Seattle IASP1994,209-214 https:\/\/www.iasppain.org\/PublicationsNews\/Content.aspx?ItemNumber=1673","journal-title":"Part III: Pain Terms, A Current List with Definitions and Notes on Usage Classification of Chronic Pain, Second Edition, IASP Task Force on Taxonomy, edited by H Merskey and N Bogduk, ISAP Press, Seattle"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(99)01311-2","volume":"353","author":"Loeser J.D.","year":"1999","unstructured":"Loeser J.D.; Melzack R.; Pain: an overview. Lancet 1999,353(9164),1607-1609","journal-title":"Lancet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1155\/2006\/197616","volume":"11","author":"von Baeyer C.L.","year":"2006","unstructured":"von Baeyer C.L.; Children\u2019s self-reports of pain intensity: scale selection, limitations and interpretation. Pain Res Manag 2006,11(3),157-162","journal-title":"Pain Res Manag"},{"key":"ref=24","author":"Hester N.","unstructured":"Hester N.; Foster R.; Kristensen K.; Measurement of pain in children: Generalizability and validity of the Pain Ladder and the Poker Chip Tool. Tyler D, Krane E, eds. Pediatric Pain, Vol 15: Advances in Pain Research and Therapy; New York: Raven Press, 1990, pp. 79-84"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1043454214555197","volume":"32","author":"Mahon P.","year":"2015","unstructured":"Mahon P.; Holsti L.; Siden H.; Strahlendorf C.; Turnham L.; Giaschi D.; Using colors to assess pain in toddlers: validation of \u201cthe rainbow pain scale\u201d-a proof-of-principle study. J Pediatr Oncol Nurs 2015,32(1),40-46","journal-title":"J Pediatr Oncol Nurs"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0304-3959(01)00314-1","volume":"93","author":"Hicks C.L.","year":"2001","unstructured":"Hicks C.L.; von Baeyer C.L.; Spafford P.A.; van Korlaar I.; Goodenough B.; The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain 2001,93(2),173-183","journal-title":"Pain"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/00006199-199211000-00013","volume":"41","author":"Cline M.E.","year":"1992","unstructured":"Cline M.E.; Herman J.; Shaw E.R.; Morton R.D.; Standardization of the visual analogue scale. Nurs Res 1992,41(6),378-380","journal-title":"Nurs Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pain.2009.03.002","volume":"143","author":"von Baeyer C.L.","year":"2009","unstructured":"von Baeyer C.L.; Spagrud L.J.; McCormick J.C.; Choo E.; Neville K.; Connelly M.A.; Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children\u2019s self-reports of pain intensity. Pain 2009,143(3),223-227","journal-title":"Pain"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jpain.2011.12.010","volume":"13","author":"Pag\u00e9 M.G.","year":"2012","unstructured":"Pag\u00e9 M.G.; Katz J.; Stinson J.; Isaac L.; Martin-Pichora A.L.; Campbell F.; Validation of the numerical rating scale for pain intensity and unpleasantness in pediatric acute postoperative pain: sensitivity to change over time. J Pain 2012,13(4),359-369","journal-title":"J Pain"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/nur.4770140507","volume":"14","author":"Tesler M.D.","year":"1991","unstructured":"Tesler M.D.; Savedra M.C.; Holzemer W.L.; Wilkie D.J.; Ward J.A.; Paul S.M.; The word-graphic rating scale as a measure of children\u2019s and adolescents\u2019 pain intensity. Res Nurs Health 1991,14(5),361-371","journal-title":"Res Nurs Health"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00586-005-1044-x","volume":"15","author":"Haefeli M.","year":"2006","unstructured":"Haefeli M.; Elfering A.; Pain assessment. Eur Spine J 2006,15(1),17-24","journal-title":"Eur Spine J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.20986\/resed.2018.3632\/2017","volume":"25","author":"Vicente H.M.T.","year":"2018","unstructured":"Vicente H.M.T.; Delgado B.S.; Bandr\u00e9s M.F.; Ram\u00edrez I.; de la Torre M.V.; Capdevila G.L.; Valoraci\u00f3n del dolor. revisi\u00f3n comparativa de escalas y cuestionarios. Rev Soc Esp Dolor 2018,25(4),228-236","journal-title":"Rev Soc Esp Dolor"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/S0140-6736(99)01313-6","volume":"353","author":"Besson J.M.","year":"1999","unstructured":"Besson J.M.; The neurobiology of pain. Lancet 1999,353(9164),1610-1615","journal-title":"Lancet"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1185\/03007995.2013.810615","volume":"29","author":"Pergolizzi J.","year":"2013","unstructured":"Pergolizzi J.; Ahlbeck K.; Aldington D.; Alon E.; Coluzzi F.; Dahan A.; Huygen F.; Kocot-K\u0119pska M.; Mangas A.C.; Mavrocordatos P.; Morlion B.; M\u00fcller-Schwefe G.; Nicolaou A.; P\u00e9rez Hern\u00e1ndez C.; Sich\u00e8re P.; Sch\u00e4fer M.; Varrassi G.; The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment. Curr Med Res Opin 2013,29(9),1127-1135","journal-title":"Curr Med Res Opin"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0025-7125(16)30863-X","volume":"71","author":"Payne R.","year":"1987","unstructured":"Payne R.; Anatomy, physiology, and neuropharmacology of cancer pain. Med Clin North Am 1987,71(2),153-167","journal-title":"Med Clin North Am"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.12688\/f1000research.10817.1","volume":"6","author":"Chwistek M.","year":"2017","unstructured":"Chwistek M.; Recent advances in understanding and managing cancer pain. F1000 Res 2017,6,945","journal-title":"F1000 Res"},{"key":"ref=37","first-page":"105","volume":"1816","author":"Mancino M.","year":"2011","unstructured":"Mancino M.; Ametller E.; Gasc\u00f3n P.; Almendro V.; The neuronal influence on tumor progression. Biochim Biophys Acta 2011,1816(2),105-118","journal-title":"Biochim Biophys Acta"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/joacp.JOACP_389_15","volume":"34","author":"Patel M.K.","year":"2018","unstructured":"Patel M.K.; Kaye A.D.; Urman R.D.; Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol 2018,34(1),111-116","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pharmthera.2011.01.005","volume":"130","author":"Miller K.E.","year":"2011","unstructured":"Miller K.E.; Hoffman E.M.; Sutharshan M.; Schechter R.; Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms. Pharmacol Ther 2011,130(3),283-309","journal-title":"Pharmacol Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13578-020-00393-4","volume":"10","author":"Du X.","year":"2020","unstructured":"Du X.; Li J.; Li M.; Yang X.; Qi Z.; Xu B.; Liu W.; Xu Z.; Deng Y.; Research progress on the role of type I vesicular glutamate transporter (VGLUT1) in nervous system diseases. Cell Biosci 2020,10,26","journal-title":"Cell Biosci"},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.1177\/1744806917697011","volume":"13","author":"Nencini S.","year":"2017","unstructured":"Nencini S.; Ringuet M.; Kim D.H.; Chen Y.J.; Greenhill C.; Ivanusic J.J.; Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain. Mol Pain 2017,13","journal-title":"Mol Pain"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/ejn.12462","volume":"39","author":"Mantyh P.W.","year":"2014","unstructured":"Mantyh P.W.; The neurobiology of skeletal pain. Eur J Neurosci 2014,39(3),508-519","journal-title":"Eur J Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neuroscience.2011.01.039","volume":"178","author":"Casta\u00f1eda-Corral G.","year":"2011","unstructured":"Casta\u00f1eda-Corral G.; Jimenez-Andrade J.M.; Bloom A.P.; Taylor R.N.; Mantyh W.G.; Kaczmarska M.J.; Ghilardi J.R.; Mantyh P.W.; The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience 2011,178,196-207","journal-title":"Neuroscience"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1749-6632.2009.05429.x","volume":"1198","author":"Jimenez-Andrade J.M.","year":"2010","unstructured":"Jimenez-Andrade J.M.; Mantyh W.G.; Bloom A.P.; Ferng A.S.; Geffre C.P.; Mantyh P.W.; Bone cancer pain. Ann N Y Acad Sci 2010,1198,173-181","journal-title":"Ann N Y Acad Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1158\/0008-5472.CAN-15-3545","volume":"77","author":"Hiasa M.","year":"2017","unstructured":"Hiasa M.; Okui T.; Allette Y.M.; Ripsch M.S.; Sun-Wada G.H.; Wakabayashi H.; Roodman G.D.; White F.A.; Yoneda T.; Bone pain induced by multiple myeloma is reduced by targeting V-ATPase and ASIC3. Cancer Res 2017,77(6),1283-1295","journal-title":"Cancer Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","volume":"88","author":"Argyriou A.A.","year":"2014","unstructured":"Argyriou A.A.; Cavaletti G.; Bruna J.; Kyritsis A.P.; Kalofonos H.P.; Bortezomib-induced peripheral neurotoxicity: an update. Arch Toxicol 2014,88(9),1669-1679","journal-title":"Arch Toxicol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1080\/14656566.2017.1392508","volume":"18","author":"Schutzer-Weissmann J.","year":"2017","unstructured":"Schutzer-Weissmann J.; Farquhar-Smith P.; Post-herpetic neuralgia - a review of current management and future directions. Expert Opin Pharmacother 2017,18(16),1739-1750","journal-title":"Expert Opin Pharmacother"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.2174\/092986711796391660","volume":"18","author":"Coluzzi F.","year":"2011","unstructured":"Coluzzi F.; Di Bussolo E.; Mandatori I.; Mattia C.; Bone metastatic disease: taking aim at new therapeutic targets. Curr Med Chem 2011,18(20),3093-3115","journal-title":"Curr Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"Berenson J.R.","year":"1996","unstructured":"Berenson J.R.; Lichtenstein A.; Porter L.; Dimopoulos M.A.; Bordoni R.; George S.; Lipton A.; Keller A.; Ballester O.; Kovacs M.J.; Blacklock H.A.; Bell R.; Simeone J.; Reitsma D.J.; Heffernan M.; Seaman J.; Knight R.D.; Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996,334(8),488-493","journal-title":"N Engl J Med"},{"key":"ref=50","first-page":"377","volume":"7","author":"Rosen L.S.","year":"2001","unstructured":"Rosen L.S.; Gordon D.; Kaminski M.; Howell A.; Belch A.; Mackey J.; Apffelstaedt J.; Hussein M.; Coleman R.E.; Reitsma D.J.; Seaman J.J.; Chen B.L.; Ambros Y.; Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001,7(5),377-387","journal-title":"Cancer J"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","volume":"11","author":"Gimsing P.","year":"2010","unstructured":"Gimsing P.; Carlson K.; Turesson I.; Fayers P.; Waage A.; Vangsted A.; Mylin A.; Gluud C.; Juliusson G.; Gregersen H.; Hjorth-Hansen H.; Nesthus I.; Dahl I.M.; Westin J.; Nielsen J.L.; Knudsen L.M.; Ahlberg L.; Hjorth M.; Abildgaard N.; Andersen N.F.; Linder O.; Wisl\u00f8ff F.; Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 2010,11(10),973-982","journal-title":"Lancet Oncol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/SPC.0b013e32830baac2","volume":"2","author":"Lipton A.","year":"2008","unstructured":"Lipton A.; Jun S.; RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2008,2(3),197-203","journal-title":"Curr Opin Support Palliat Care"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","volume":"12","author":"Body J.J.","year":"2006","unstructured":"Body J.J.; Facon T.; Coleman R.E.; Lipton A.; Geurs F.; Fan M.; Holloway D.; Peterson M.C.; Bekker P.J.; A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006,12(4),1221-1228","journal-title":"Clin Cancer Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"9426","DOI":"10.1158\/0008-5472.CAN-05-0826","volume":"65","author":"Halvorson K.G.","year":"2005","unstructured":"Halvorson K.G.; Kubota K.; Sevcik M.A.; Lindsay T.H.; Sotillo J.E.; Ghilardi J.R.; Rosol T.J.; Boustany L.; Shelton D.L.; Mantyh P.W.; A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005,65(20),9426-9435","journal-title":"Cancer Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.pain.2005.02.022","volume":"115","author":"Sevcik M.A.","year":"2005","unstructured":"Sevcik M.A.; Ghilardi J.R.; Peters C.M.; Lindsay T.H.; Halvorson K.G.; Jonas B.M.; Kubota K.; Kuskowski M.A.; Boustany L.; Shelton D.L.; Mantyh P.W.; Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005,115(1-2),128-141","journal-title":"Pain"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40122-013-0009-8","volume":"2","author":"Sj\u00f6lund K.F.","year":"2013","unstructured":"Sj\u00f6lund K.F.; Yang R.; Lee K.H.; Resnick M.; Randomized study of pregabalin in patients with cancer-induced bone pain. Pain Ther 2013,2(1),37-48","journal-title":"Pain Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/SPC.0000000000000263","volume":"11","author":"Lim F.M.Y.","year":"2017","unstructured":"Lim F.M.Y.; Bobrowski A.; Agarwal A.; Silva M.F.; Use of corticosteroids for pain control in cancer patients with bone metastases: a comprehensive literature review. Curr Opin Support Palliat Care 2017,11(2),78-87","journal-title":"Curr Opin Support Palliat Care"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/BSD.0000000000000528","volume":"30","author":"Kumar A.","year":"2017","unstructured":"Kumar A.; Weber M.H.; Gokaslan Z.; Wolinsky J.P.; Schmidt M.; Rhines L.; Fehlings M.G.; Laufer I.; Sciubba D.M.; Clarke M.J.; Sundaresan N.; Verlaan J.J.; Sahgal A.; Chou D.; Fisher C.G.; Metastatic spinal cord compression and steroid treatment: a systematic review. Clin Spine Surg 2017,30(4),156-163","journal-title":"Clin Spine Surg"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","volume":"29","author":"Fallon M.","year":"2018","unstructured":"Fallon M.; Giusti R.; Aielli F.; Hoskin P.; Rolke R.; Sharma M.; Ripamonti C.I.; Management of cancer pain in adult patients. ESMO Clinical Practice Guidelines Ann Oncol ESMO Guidelines Committee2018,29,iv166-iv191","journal-title":"ESMO Clinical Practice Guidelines Ann Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-neuro-080317-061522","volume":"41","author":"Corder G.","year":"2018","unstructured":"Corder G.; Castro D.C.; Bruchas M.R.; Scherrer G.; Endogenous and exogenous opioids in pain. Annu Rev Neurosci 2018,41,453-473","journal-title":"Annu Rev Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/bs.pbr.2018.07.002","volume":"239","author":"Ferdousi M.","year":"2018","unstructured":"Ferdousi M.; Finn D.P.; Stress-induced modulation of pain: Role of the endogenous opioid system. Prog Brain Res 2018,239,121-177","journal-title":"Prog Brain Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev.pharmtox.40.1.389","volume":"40","author":"Law P.Y.","year":"2000","unstructured":"Law P.Y.; Wong Y.H.; Loh H.H.; Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000,40,389-430","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/JPR.S83490","volume":"8","author":"Coluzzi F.","year":"2015","unstructured":"Coluzzi F.; Raffa R.B.; Pergolizzi J.; Rocco A.; Locarini P.; Cenfra N.; Cimino G.; Mattia C.; Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res 2015,8,229-238","journal-title":"J Pain Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/TCRM.S79409","volume":"11","author":"Coluzzi F.","year":"2015","unstructured":"Coluzzi F.; Pergolizzi J.; Raffa R.B.; Mattia C.; The unsolved case of \u201cbone-impairing analgesics\u201d: the endocrine effects of opioids on bone metabolism. Ther Clin Risk Manag 2015,11,515-523","journal-title":"Ther Clin Risk Manag"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s40265-018-0980-9","volume":"78","author":"Coluzzi F.","year":"2018","unstructured":"Coluzzi F.; Assessing and treating chronic pain in patients with end-stage renal disease. Drugs 2018,78(14),1459-1479","journal-title":"Drugs"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jcv.2015.10.018","volume":"73","author":"Kim J.W.","year":"2015","unstructured":"Kim J.W.; Min C.K.; Mun Y.C.; Park Y.; Kim B.S.; Nam S.H.; Koh Y.; Kwon J.H.; Choe P.G.; Park W.B.; Kim I.; Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. J Clin Virol 2015,73,64-69","journal-title":"J Clin Virol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2147\/DDDT.S142630","volume":"11","author":"Pickering G.","year":"2017","unstructured":"Pickering G.; Martin E.; Tiberghien F.; Delorme C.; Mick G.; Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther 2017,11,2709-2718","journal-title":"Drug Des Devel Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1523\/JNEUROSCI.3815-04.2005","volume":"25","author":"Ghilardi J.R.","year":"2005","unstructured":"Ghilardi J.R.; R\u00f6hrich H.; Lindsay T.H.; Sevcik M.A.; Schwei M.J.; Kubota K.; Halvorson K.G.; Poblete J.; Chaplan S.R.; Dubin A.E.; Carruthers N.I.; Swanson D.; Kuskowski M.; Flores C.M.; Julius D.; Mantyh P.W.; Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 2005,25(12),3126-3131","journal-title":"J Neurosci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/bja\/aer260","volume":"107","author":"Anand P.","year":"2011","unstructured":"Anand P.; Bley K.; Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011,107(4),490-502","journal-title":"Br J Anaesth"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/1060028017706373","volume":"51","author":"Moore D.C.","year":"2017","unstructured":"Moore D.C.; Pellegrino A.E.; Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother 2017,51(9),797-803","journal-title":"Ann Pharmacother"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00520-015-2834-2","volume":"24","author":"Xu H.","year":"2016","unstructured":"Xu H.; Gong Q.; Vogl F.D.; Reiner M.; Page J.H.; Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Support Care Cancer 2016,24(2),723-730","journal-title":"Support Care Cancer"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00280-018-3607-7","volume":"82","author":"Lower E.E.","year":"2018","unstructured":"Lower E.E.; Charif M.; Bartelt M.; Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study. Cancer Chemother Pharmacol 2018,82(1),165-170","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00520-017-3959-2","volume":"26","author":"Kirshner J.J.","year":"2018","unstructured":"Kirshner J.J.; McDonald M.C.; Kruter F.; Guinigundo A.S.; Vanni L.; Maxwell C.L.; Reiner M.; Upchurch T.E.; Garcia J.; Morrow P.K.; NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer 2018,26(4),1323-1334","journal-title":"Support Care Cancer"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.12968\/bjon.2019.28.4.S4","volume":"28","author":"Duggan C.","year":"2019","unstructured":"Duggan C.; Murphy L.; Costello V.; Leary E.O.; Yousif A.D.; Blazkova S.; Dowling M.; Oral loratadine in the management of G-CSF-induced bone pain: a pilot study. Br J Nurs 2019,28(4),S4-S11","journal-title":"Br J Nurs"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00520-016-3465-y","volume":"25","author":"Gavioli E.","year":"2017","unstructured":"Gavioli E.; Abrams M.; Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade. Support Care Cancer 2017,25(3),817-822","journal-title":"Support Care Cancer"},{"key":"ref=76","year":"2020","unstructured":"Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization National Library of Medicine (U.S.)NCT04211259. Available at: \n2020","journal-title":"Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization"},{"key":"ref=77","year":"2014","unstructured":"Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies National Library of Medicine (U.S.)NCT02305979. Available at: \n2014","journal-title":"Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub4","volume":"12","author":"Mhaskar R.","year":"2017","unstructured":"Mhaskar R.; Kumar A.; Miladinovic B.; Djulbegovic B.; Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev 2017,12(12)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=79","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv197","volume":"107","author":"Hoskin P.","year":"2015","unstructured":"Hoskin P.; Sundar S.; Reczko K.; Forsyth S.; Mithal N.; Sizer B.; Bloomfield D.; Upadhyay S.; Wilson P.; Kirkwood A.; Stratford M.; Jitlal M.; Hackshaw A.; A multicenter randomized trial of ibandronate compared with single-dose radiotherapy for localized metastatic bone pain in prostate cancer. JNCI. J Natl Cancer Inst 2015,107(10)","journal-title":"J Natl Cancer Inst"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3892\/ol.2018.8804","volume":"16","author":"Wang G.","year":"2018","unstructured":"Wang G.; Chen J.; Ma R.; Xu W.; Yan C.; Niu C.; Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases. Oncol Lett 2018,16(2),1696-1700","journal-title":"Oncol Lett"},{"key":"ref=81","author":"Purnell H.","year":"2013","unstructured":"Purnell H.; Monson K.;  Single-Dose local radiation therapy compared with ibandronate in treating patients with localized metastatic bone pain Identifier NCT00082927 Available at: \n2013","journal-title":"Single-Dose local radiation therapy compared with ibandronate in treating patients with localized metastatic bone pain"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000338369","volume":"35","author":"Altundag K.","year":"2012","unstructured":"Altundag K.; Dizdar O.; Ozsaran Z.; Ozkok S.; Saip P.; Eralp Y.; Komurcu S.; Kuzhan O.; Ozguroglu M.; Karahoca M.; Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain. Onkologie 2012,35(5),254-258","journal-title":"Onkologie"},{"key":"ref=83","year":"2015","unstructured":"A study to assess the short term efficacy of intravenous ibandronate (bondronat) in participants with metastatic bone pain due to breast cancer National Library of Medicine (U.S.)Identifier NCT02553707. Available at: \n2015","journal-title":"A study to assess the short term efficacy of intravenous ibandronate (bondronat) in participants with metastatic bone pain due to breast cancer"},{"key":"ref=84","year":"2014","unstructured":"A study of loading doses of intravenous bondronat (ibandronate) in patients with breast cancer and malignant bone disease National Library of Medicine (U.S.)Identifier NCT00502736. Available at: \n2014","journal-title":"A study of loading doses of intravenous bondronat (ibandronate) in patients with breast cancer and malignant bone disease"},{"key":"ref=85","year":"2014","unstructured":"A study of loading doses of intravenous bondronat (ibandronate) in patients with breast cancer and metastatic bone disease National Library of Medicine (U.S.)Identifier NCT00478270. Available at: \n2014","journal-title":"A study of loading doses of intravenous bondronat (ibandronate) in patients with breast cancer and metastatic bone disease"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","volume":"76","author":"Saad F.","year":"2010","unstructured":"Saad F.; Eastham J.; Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 2010,76(5),1175-1181","journal-title":"Urology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/jrr\/rry092","volume":"60","author":"Choi J.","year":"2019","unstructured":"Choi J.; Lee E.J.; Yang S.H.; Im, Y.R.; Seong, J. A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers. J Radiat Res (Tokyo) 2019,60(2),242-248","journal-title":"J Radiat Res (Tokyo)"},{"key":"ref=88","year":"2014","unstructured":"Study comparing full-dose radiotherapy versus reduced dose in the management of bone metastasis in patients with breast cancer receiving zoledronic acid National Library of Medicine (U.S.)Identifier NCT00172029.2014","journal-title":"Study comparing full-dose radiotherapy versus reduced dose in the management of bone metastasis in patients with breast cancer receiving zoledronic acid"},{"key":"ref=89","year":"2017","unstructured":"Efficacy and safety of zoledronic acid in the treatment of bone metastases-related pain in patients with prostate cancer (TRAPEZE) National Library of Medicine (U.S.)Identifier NCT00375648. Available at: \n2017","journal-title":"Efficacy and safety of zoledronic acid in the treatment of bone metastases-related pain in patients with prostate cancer (TRAPEZE)"},{"key":"ref=90","year":"2017","unstructured":"A study to assess the efficacy of intravenous\/oral bondronat (ibandronate) in patients with metastatic bone disease experiencing moderate to severe pain National Library of Medicine (U.S.)Identifier NCT00099177. Available at: \n2017","journal-title":"A study to assess the efficacy of intravenous\/oral bondronat (ibandronate) in patients with metastatic bone disease experiencing moderate to severe pain"},{"key":"ref=91","year":"2017","unstructured":"Study to assess the efficacy of intravenous bondronat (ibandronate) in patients with malignant and painful bone disease National Library of Medicine (U.S.)Identifier NCT00099203. Available at: \n2017","journal-title":"Study to assess the efficacy of intravenous bondronat (ibandronate) in patients with malignant and painful bone disease"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/j.pain.0000000000000115","volume":"156","author":"Brown D.C.","year":"2015","unstructured":"Brown D.C.; Agnello K.; Iadarola M.J.; Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain. Pain 2015,156(6),1018-1024","journal-title":"Pain"},{"key":"ref=93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100261","volume":"19","author":"Danson S.","year":"2019","unstructured":"Danson S.; Mulvey M.R.; Turner L.; Horsman J.; Escott K.; Coleman R.E.; Ahmedzai S.H.; Bennett M.I.; Andrew D.; An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. J Bone Oncol 2019,19","journal-title":"J Bone Oncol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2015.63.8221","volume":"34","author":"Fallon M.","year":"2016","unstructured":"Fallon M.; Hoskin P.J.; Colvin L.A.; Fleetwood-Walker S.M.; Adamson D.; Byrne A.; Laird B.J.; Randomized double-blind trial of pregabalin versus placebo in conjunction with palliative radiotherapy for cancer-induced bone pain. J Clin Oncol 2016,34(6),550-556","journal-title":"J Clin Oncol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-94-017-7537-3_9","volume":"904","author":"Xu L.","year":"2016","unstructured":"Xu L.; Zhang Y.; Huang Y.; Advances in the treatment of neuropathic pain. Adv Exp Med Biol 2016,904,117-129","journal-title":"Adv Exp Med Biol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0889-8588(02)00016-3","volume":"16","author":"Vielhaber A.","year":"2002","unstructured":"Vielhaber A.; Portenoy R.K.; Advances in cancer pain management. Hematol Oncol Clin North Am 2002,16(3),527-541","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.critrevonc.2017.12.016","volume":"122","author":"Mercadante S.","year":"2018","unstructured":"Mercadante S.; Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review. Crit Rev Oncol Hematol 2018,122,60-63","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(11)60236-5","volume":"25;377","author":"Portenoy R.K.","year":"2011","unstructured":"Portenoy R.K.;  Treatment of cancer pain Lancet 2011,25;377(9784),2236-2247","journal-title":"Treatment of cancer pain Lancet"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3322\/caac.21453","volume":"68","author":"Scarborough B.M.","year":"2018","unstructured":"Scarborough B.M.; Smith C.B.; Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 2018,68(3),182-196","journal-title":"CA Cancer J Clin"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11912-017-0570-0","volume":"19","author":"Liu W.C.","year":"2017","unstructured":"Liu W.C.; Zheng Z.X.; Tan K.H.; Meredith G.J.; Multidimensional treatment of cancer pain. Curr Oncol Rep 2017,19(2),10","journal-title":"Curr Oncol Rep"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.TPM.0000488727.32096.c9","volume":"31","author":"Dipan P.","year":"2016","unstructured":"Dipan P.; Saurabh D.; Weber G.; Neuromodulation of cancer pain: current concepts and treatment strategies. Topics in Pain Management 2016,31(12),1-10","journal-title":"Topics in Pain Management"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jpainsymman.2008.03.017","volume":"37","author":"Searle R.D.","year":"2009","unstructured":"Searle R.D.; Bennett M.I.; Johnson M.I.; Callin S.; Radford H.; Transcutaneous electrical nerve stimulation (TENS) for cancer bone pain. J Pain Symptom Manage 2009,37(3),424-428","journal-title":"J Pain Symptom Manage"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jpain.2009.08.002","volume":"11","author":"Bennett M.I.","year":"2010","unstructured":"Bennett M.I.; Johnson M.I.; Brown S.R.; Radford H.; Brown J.M.; Searle R.D.; Feasibility study of Transcutaneous Electrical Nerve Stimulation (TENS) for cancer bone pain. J Pain 2010,11(4),351-359","journal-title":"J Pain"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11916-020-0846-1","volume":"24","author":"Mokhtari T.","year":"2020","unstructured":"Mokhtari T.; Ren Q.; Li N.; Wang F.; Bi Y.; Hu L.; Transcutaneous electrical nerve stimulation in relieving neuropathic pain: basic mechanisms and clinical applications. Curr Pain Headache Rep 2020,24(4),14","journal-title":"Curr Pain Headache Rep"},{"key":"ref=105","author":"Teoli D.","year":"2020","unstructured":"Teoli D.; An J.;  Transcutaneous Electrical Nerve Stimulation (TENS) StatPearls 2020","journal-title":"Transcutaneous Electrical Nerve Stimulation (TENS) StatPearls"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X18666201111112748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187838\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X18666201111112748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T12:33:00Z","timestamp":1655382780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187838\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666201111112748","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}